Onyx

A research collective building a virtual immune system to understand immune health, aging, and disease for precision medicine.

Website: https://www.onyx.bio/

Cover Block

Open sources

Field	Value
Name	Onyx
Tagline	A research collective building a virtual immune system to understand immune health, aging, and disease for precision medicine.
Headquarters	Berkeley, Calif. [onyx.bio]
Founded	2024 [Crunchbase]
Stage	Seed [Crunchbase, 2026]
Business Model	Other
Technology	Biotech / Life Sciences
Funding label	$8M Seed Round [Crunchbase, 2026]
Total disclosed	~$8,000,000 [Crunchbase, 2026]

What an Investor Needs First

PUBLIC Onyx is a Berkeley-based biotech startup founded in 2024 that is trying to build a "virtual immune system" from longitudinal multiomics and clinical-context data, a proposition that merits attention because the company appears to be positioning itself at the intersection of autoimmune research infrastructure and precision medicine development [Crunchbase, 2026] [onyx.bio] [f4.fund, 2026]. The public record is still thin, but the company describes itself as a research collective of citizens and scientists focused on understanding immune health, aging, and disease, with an initial emphasis on generating immune datasets that track how patients respond over time rather than offering a direct clinical care product [onyx.bio] [onyx.bio, retrieved].

The product thesis is straightforward even if the underlying execution burden is high. Onyx says it offers vertically integrated multiomics datasets with longitudinal patient records across autoimmune indications and presents that dataset layer as the basis for faster, safer precision medicine development, which suggests differentiation will rest less on a software interface than on data quality, patient follow-up, and disease-specific research workflows [onyx.bio] [onyx.bio, retrieved] [f4.fund, 2026].

Team visibility remains limited in public sources.

Funding is clearer than operations. Crunchbase and Caplight indicate roughly $8 million in disclosed seed financing, while one investor directory profile places Onyx within biotech and life sciences; the available public evidence does not firmly identify the lead investor, and the reported business model is best understood as a mix of research services and eventual licensing around proprietary models or workflows rather than a traditional therapeutics pipeline [Crunchbase, 2026] [Caplight, 2026] [f4.fund, 2026].

The next 12 to 18 months will likely matter most on three fronts: whether Onyx can show named research partnerships or repeat study participation, whether its autoimmune data asset matures into something buyers treat as proprietary rather than interchangeable, and whether the company can clarify the founding team and go-to-market motion without relying primarily on company-authored descriptions [onyx.bio] [onyx.bio, retrieved] [Crunchbase, 2026]. At this stage, the company is interesting because the category can produce real strategic value if the data layer compounds, but the present public file supports a watchful stance more on thesis than on demonstrated traction [onyx.bio] [f4.fund, 2026].

Claim stands unchecked -- This section relies materially on company website claims, with partial corroboration from Crunchbase, Caplight, LinkedIn, and an investor directory.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Other
Technology Type	Biotech / Life Sciences
Funding	$8M Seed Round

Inside the Company

PUBLIC

Onyx appears to be a newly formed biotech effort centered on one narrow claim: building a "virtual immune system" that links longitudinal patient records with multiomic data for precision medicine research [onyx.bio, retrieved] [Crunchbase]. The company is based in Berkeley, California and was founded in 2024, according to its website and Crunchbase profile [onyx.bio, retrieved] [Crunchbase]. Public materials describe Onyx as a research collective studying immune health, aging, and disease, with an early emphasis on autoimmune indications rather than a clinical care offering [onyx.bio, retrieved] [Crunchbase].

The public milestone record is still thin, which is normal at this stage. The company website frames the current product surface around researcher access to vertically integrated multiomics datasets and longitudinal immune data, while its privacy and FAQ materials state that medical care remains between users and their own physicians and that Onyx does not provide clinical testing or health advice [onyx.bio, retrieved]. Crunchbase lists roughly $8 million in disclosed seed financing, giving the company one verifiable capital event in the public record, but the available sources in this section do not identify a legal entity name, founders, or a dated sequence of operating milestones beyond the 2024 founding and seed-stage status [Crunchbase] [onyx.bio, retrieved].

Partially corroborated -- Confirmed in part by Crunchbase and the company website; several material company details remain company-described or uncited in public records.

Under the Hood

MIXED

The product story is straightforward at the top line, even if the technical substrate remains only lightly documented in public. Onyx describes itself as a research collective building a "virtual immune system" and says the core output is longitudinal, multiomic patient data linked to clinical context for use in precision medicine research [onyx.bio]. On its researcher-facing materials, the company says it offers vertically integrated multiomics datasets with longitudinal patient records across autoimmune indications, while its launch post frames the same system as a model of how real people respond to infection, inflammation, and treatment [onyx.bio].

What is public today points more to a data and research workflow than to a clinical product. Onyx says it runs research studies intended to help scientists better understand autoimmune conditions, and a rheumatoid arthritis study page plus prescreen flow indicate active participant recruitment around specific indications [onyx.bio]. The company also states that medical care remains between participants and their own physicians, and that it does not provide clinical testing or health advice, which helps bound the current product scope: this appears to be a research data collection and modeling platform rather than a care delivery or diagnostics offering [onyx.bio].

There is modest third-party corroboration for the same positioning, but not yet enough to validate technical differentiation in detail. Crunchbase describes Onyx Bio as a biotechnology company building a virtual immune system by integrating multiomics data with longitudinal patient records, and F4 Fund similarly characterizes the company as generating longitudinal multi-omics data in clinical context to profile autoimmune disease progression [Crunchbase, 2026] [F4 Fund, 2026]. A single surfaced Clinical Research Coordinator listing is directionally consistent with a study-operations layer, though it does not establish the underlying software stack or model architecture [SupportFinity]. For now, the investable question is less whether the company has articulated a clear product concept, it has, and more whether it can show that its dataset quality, consent framework, and downstream research utility are meaningfully better than standard cohort assembly and multiomics vendors.

Partially corroborated -- Product positioning is corroborated by company materials and partial third-party profiles, but most capability detail remains company-described.

Market Research

PUBLIC The market matters now because immune-focused drug development is colliding with two scarcities at once: high-quality longitudinal human data and models that can connect molecular signals to real disease trajectories, a gap Onyx is explicitly trying to fill with multiomics datasets tied to autoimmune patient records [onyx.bio, retrieved] [Crunchbase, 2026].

Public sourcing does not support a direct TAM, SAM, or SOM estimate for Onyx’s specific niche, and no named third-party market study was provided in the source set. That leaves the market definition narrower and more qualitative than usual. Based on the company’s own description, the relevant commercial surface sits at the intersection of precision medicine research, translational immunology, and data infrastructure for biopharma R&D, with Onyx positioning itself around longitudinal multiomics data for autoimmune disease research rather than around diagnostics, care delivery, or consumer wellness [onyx.bio, retrieved].

The nearest visible demand driver in the public record is the growing need for datasets that are both biologically deep and clinically contextual. Onyx says it is building vertically integrated multiomics datasets with longitudinal patient records across autoimmune indications, and says those datasets are intended for researchers developing precision medicines [onyx.bio, retrieved]. If that description is directionally accurate, the tailwind is straightforward: drug developers need cleaner links between patient heterogeneity, disease progression, and treatment response, especially in immune-mediated disease where snapshot data often miss temporal variation [onyx.bio, retrieved].

A second tailwind is workflow convergence. Onyx describes a "virtual immune system" intended to model how real people respond to infection, inflammation, and treatment, which places it adjacent to computational biology platforms, contract research data generation, and licensed research datasets rather than a single software category [onyx.bio, retrieved]. That adjacency matters because buyers may not budget this as pure software spend. Depending on how the product is sold, demand could come from translational teams, biomarker groups, external innovation functions, or platform biology budgets, with different sales cycles and validation thresholds.

Market lens	Publicly supported claim	Source
Core market	Precision medicine research informed by longitudinal immune data	[onyx.bio, retrieved]
Disease focus	Autoimmune indications are specifically referenced	[onyx.bio, retrieved]
Product adjacency	Multiomics data infrastructure and modeling, not clinical care delivery	[onyx.bio, retrieved]
Revenue adjacency	Service contracts and licensing have been described as the business model (estimated characterization, source claim only)	[f4.fund, 2026]

The table points to a market that is real but still loosely bounded in public materials. The practical implication is that investors should read Onyx less as a broad "AI for biotech" claim and more as a narrower bet on proprietary immune datasets becoming valuable inputs to drug discovery and development.

Substitute and adjacent markets are easier to identify than exact market size. Onyx could compete indirectly with contract research organizations that generate study data, with data brokers or specialty dataset companies serving biopharma, and with internal platform biology teams at larger drug developers that build similar longitudinal resources themselves. The company also sits near patient recruitment and decentralized research workflows because its public materials reference paid research studies and condition-specific enrollment surfaces, including rheumatoid arthritis and autoimmune screening flows [onyx.bio, retrieved].

Regulatory and macro forces cut both ways. The helpful side is that precision medicine programs increasingly require better evidence linking biomarkers to outcomes, which tends to raise the value of well-annotated longitudinal datasets. The constraint is that human-subject data businesses face persistent scrutiny around consent, privacy, and downstream use, and Onyx itself emphasizes that it does not provide medical care, clinical testing, or health advice, keeping care decisions between participants and their own physicians [onyx.bio, retrieved]. That framing reduces some clinical-service ambiguity, but it does not remove the diligence burden around data rights, study governance, and whether research-grade data can support repeatable commercial demand.

Claim stands unchecked -- This section relies primarily on company materials and one secondary profile, with no independent third-party market sizing report in the provided sources.

Competition and Substitutes

MIXED Onyx is positioned less against a clearly disclosed set of named startup peers than against a stack of alternatives in translational immunology, clinical data generation, and outsourced research, which makes the present competitive question less about logo-to-logo displacement and more about whether its longitudinal multiomics dataset can become a preferred input for precision-medicine work in autoimmune disease [onyx.bio].

The competitive map breaks into three practical segments. The first is incumbent life-science infrastructure: academic medical centers, hospital-affiliated biobanks, and contract research organizations already generate patient samples and disease data for industry and investigator-led studies, even if the available Onyx sources do not name any one institution directly [onyx.bio]. The second is the challenger set of biotech and data companies building disease-specific or modality-specific datasets, where Onyx's public materials place it in longitudinal, clinically anchored multiomics for autoimmune conditions rather than in a single assay or single-study workflow [onyx.bio, retrieved]. The third is the adjacent substitute layer, conventional clinical trial recruitment and sponsored-study operators, because Onyx also appears to run paid research studies and participant enrollment flows, which means some buyers could view it as an alternative source of patient access rather than only a data asset provider [onyx.bio, retrieved].

Where Onyx appears to have an edge today is in the way it combines participant-facing study enrollment with researcher-facing dataset packaging. The company's public site describes vertically integrated multiomics datasets with longitudinal patient records across autoimmune indications and frames the end product as "AI-ready human immune data," which, if executed at quality, can be meaningfully harder to replicate than a one-off sample collection program because repeated sampling, clinical context, and consented longitudinal follow-up usually compound in value over time [onyx.bio, retrieved]. That said, the durability of this edge is still unproven in public evidence. The same materials that describe the data asset are company-authored, and no independent source in the provided record identifies named pharma customers, published validation studies, or exclusive channel partnerships that would make the moat look locked in rather than merely plausible [Crunchbase, 2026] [f4.fund, 2026].

The main exposure is that adjacent players with stronger existing distribution can attack the same budget line from different angles. A large CRO or a well-networked translational research group does not need to match Onyx's branding around a virtual immune system to compete for sponsored autoimmune research work; it can win on installed relationships, regulatory operations, and already-running site networks, advantages that Onyx's public record does not yet show at scale [onyx.bio, retrieved]. There is also category exposure on the product side. Onyx explicitly says medical care remains between users and their own doctors and that it does not provide clinical testing or health advice, which narrows the business away from direct clinical service revenue and toward research and data monetization, a reasonable choice but one that leaves less room to subsidize acquisition through care delivery economics [onyx.bio, retrieved].

Over the next 18 months, the most plausible competitive scenario is bifurcation between data suppliers that can prove repeatability and those that remain primarily narrative-driven. In that setup, Onyx is the likely winner if its longitudinal autoimmune datasets translate into visible researcher adoption, such as named collaborations, publications, or recurring service and licensing relationships that validate both data quality and commercial demand [onyx.bio, retrieved] [Caplight, 2026]. bio, retrieved].

Claim stands unchecked -- The section relies primarily on company-authored materials from Onyx's website and related pages, with limited third-party corroboration from Crunchbase and f4.fund,

Opportunity

PUBLIC The prize here is not a narrow research-tool business, but a position inside the data stack that biopharma and translational researchers use to understand autoimmune disease progression and, if the model broadens, immune health more generally [onyx.bio, retrieved] [Crunchbase, 2026].

The headline opportunity is straightforward: Onyx could become a specialized source of longitudinal immune-system data that is hard to reproduce quickly, particularly if its combination of multiomic profiles and clinical context proves useful in precision-medicine research [onyx.bio, retrieved] [f4.fund, 2026]. That outcome is still early and largely company-described, but it is not purely aspirational. The public materials consistently point to the same underlying asset, vertically integrated multiomics datasets linked to longitudinal patient records across autoimmune indications, and they frame the product for researchers rather than for direct care delivery [onyx.bio, retrieved]. In biotech, that distinction matters. A company that sits upstream of drug discovery and translational research can matter commercially without owning the therapeutic itself, provided the data are differentiated enough to inform target selection, patient stratification, or trial design [onyx.bio, retrieved].

A reasonable way to think about growth is as a set of branching paths rather than one linear forecast. The scenarios below are upside cases, not base-case predictions.

Scenario	What happens	Catalyst	Why it'"'"'s plausible
Autoimmune data utility layer	Onyx becomes a repeat supplier of longitudinal immune datasets for autoimmune research programs, selling access, services, or both to biopharma and academic teams	Early researcher adoption around autoimmune studies and a repeatable dataset-generation workflow [onyx.bio, retrieved]	The company already presents researcher-facing datasets with longitudinal records across autoimmune indications, which is the minimum shape of a reusable platform rather than a one-off study [onyx.bio, retrieved]
Precision-medicine model licensor	Onyx moves from dataset provider to licensing proprietary models and workflows built on top of its data asset	Internal model performance improves as more longitudinal samples and outcomes accumulate [onyx.bio, retrieved]	Public research notes describe a business model that could include service contracts and licensing, though this remains an inference rather than a confirmed commercial mix [f4.fund, 2026]
Immune-system map beyond autoimmunity	Onyx expands from autoimmune cohorts into a broader immune-health platform used across aging, inflammation, and treatment-response questions	Successful execution in one indication set creates enough credibility to recruit broader cohorts and more research buyers [onyx.bio, retrieved]	The company frames its mission around immune health, aging, and disease, not only a single condition, which gives a logical expansion path if the first datasets are scientifically valuable [onyx.bio, retrieved]

What compounding looks like here is a data flywheel, if the company can make it real. More study participants and more longitudinal observations should improve the depth of the dataset; a deeper dataset can make the research product more useful to outside scientists; stronger research utility can attract more studies, more participants, and potentially more paying counterparties [onyx.bio, retrieved]. The important point is that this is one of the few biotech-adjacent software narratives where scale can create a genuine asset rather than only sales momentum. Onyx's public materials already emphasize longitudinal, clinically anchored multiomics and repeated observation of how people respond to infection, inflammation, and treatment, which is exactly the sort of structure that becomes more valuable as records accumulate over time [onyx.bio, retrieved].

The size of the win is hard to quantify cleanly from public evidence because no market-size dataset, revenue figure, or public peer set is confirmed in the source pack. Even so, the strategic value could be substantial if the company becomes trusted infrastructure for immune-data generation and interpretation. Crunchbase lists an $8 million seed round for Onyx Bio, which at least indicates venture investors see a platform-sized ambition rather than a small services shop [Crunchbase, 2026]. In an upside case where Onyx becomes a must-have data and model layer for autoimmune and adjacent immunology research, the company could support venture-scale outcomes in the hundreds of millions of dollars in enterprise value (scenario, not a forecast). That statement rests on the general economics of proprietary research infrastructure, not on disclosed financial performance, so the gap between scientific promise and commercial proof remains the central public constraint [onyx.bio, retrieved] [Crunchbase, 2026].

Claim stands unchecked -- This section relies primarily on company materials from Onyx's website, with limited external corroboration from Crunchbase and F4 Fund on company positioning and financing.

Sources